Pilot Trial Explores Immunomodulators to Boost Pancreatic Islet Transplant Success

Autologous islet transplantation is a procedure where a patient's own pancreatic islets (insulin-producing cells) are harvested and re-infused after a total pancreatectomy to prevent post-surgical diabetes. However, a significant challenge is the poor survival and engraftment of these transplanted islets, often due to an immediate inflammatory response known as the instant blood-mediated inflammatory reaction (IBI). This study aimed to evaluate if specific immunomodulatory therapies could improve islet engraftment rates and function by mitigating this early inflammation.

At 12 months post-transplantation, the etanercept group showed a promising trend towards improved insulin independence, with 50% (4 out of 8 patients) achieving insulin independence compared to 25% (2 out of 8 patients) in the control group. The alpha-1 antitrypsin group also demonstrated a positive signal, with 37.5% (3 out of 8 patients) achieving insulin independence. The most significant finding was a 2.3-fold increase in C-peptide levels in the etanercept group compared to controls at 6 months (p=0.04), strongly suggesting better islet function and survival. Both treatment groups experienced fewer severe inflammatory markers (e.g., TNF-alpha, IL-6) in the immediate post-transplant period, although this did not reach statistical significance given the small sample size. Importantly, no significant differences in adverse event rates or severity were observed between any of the study groups.